Revenue
2025
Satellos Bioscience Inc. (MSLE)
Price$9.21Cached quote
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | — | — | — |
| Research & development | $18.4M | $14.4M | — | $2.8M |
| Operating expenses | $26.5M | $20.4M | — | $6.2M |
| Operating income | −$26.5M | −$20.4M | — | −$6.2M |
| EBITDA | −$26.5M | −$20.4M | — | −$8.1M |
| Net income | −$24.9M | −$20.6M | — | −$8.3M |
| Basic EPSper basic share | -$1.70 | -$2.16 | -$1.63 | -$2.83 |
| Diluted EPSper diluted share | -$1.70 | -$2.16 | -$1.63 | -$2.83 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
FRANKLIN RESOURCES INC | 938.67K |
Siren, L.L.C. | 892.07K |
Vivo Capital, LLC | 813.67K |
Point72 Asset Management, L.P. | 682.7K |
SPHERA FUNDS MANAGEMENT LTD. | 652.59K |
Woodline Partners LP | 500.43K |
Stonepine Capital Management, LLC | 491.62K |
MONTANOVA CAPITAL, LLC | 475K |
Avidity Partners Management LP | 387.77K |
Saturn V Capital Management LP | 350K |
Soleus Capital Management, L.P. | 314.36K |
683 Capital Management, LLC | 230.83K |
ADAR1 Capital Management, LLC | 222.56K |
AWM Investment Company, Inc. | 180K |
MILLENNIUM MANAGEMENT LLC | 152.77K |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 150K |
Empery Asset Management, LP | 107.1K |
CITADEL ADVISORS LLC | 67.74K |
MORGAN STANLEY | 25.73K |
China Universal Asset Management Co., Ltd. | 20K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
Community posts
Satellos clears FDA hurdle for a new muscular-dystrophy trial
Satellos Bioscience ($MSLE) received FDA clearance for its investigational application to study forazapadin in facioscapulohumeral muscular dystrophy. The company plans to start a randomized, placebo-controlled Phase 2 study in the fourth q ...
